Stocks Health care ALLR
NASDAQ · Health careAllarity Therapeutics, Inc. (ALLR)
It posted a net loss of $12.3M. In fiscal 2025 capital spending exceeded operating cash flow by $14.8M. At June 30, 2026 it held $17M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Allarity Therapeutics, Inc. does
Allarity Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALLR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $320K | -$11.2M | -$0.78 | -$14.8M |
| 2024 | $0 | -$24.5M | -$15.65 | -$17.7M |
| 2023 | n/a | -$11.9M | -$10.26 | -$12.7M |
| 2022 | n/a | -$16.1M | -$3,093.42 | -$16.8M |
| 2021 | n/a | -$26.6M | -$5,864.90 | n/a |
| 2021 | n/a | -$6.6M | -$2,841.47 | -$7.3M |
Where ALLR ranks in Health care
Latest SEC filings
What Allarity Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026Other event 8-K
- September 14, 2026Other event 8-K
- August 14, 2026
- August 14, 2026
- July 1, 2026
- June 22, 2026Other event 8-K
- June 2, 2026
- May 15, 2026
- May 8, 2026
- May 6, 2026Other event 8-K
Insider trades
What the people running Allarity Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 28, 2026 | Jensen ThomasCEO | Received as pay | 200,000 | - |
| January 28, 2026 | McLaughlin Gerald W.Director | Received as pay | 45,000 | - |
| January 28, 2026 | Ervin Jeffrey SCFO | Received as pay | 150,000 | - |
| January 28, 2026 | Graff Jeremy R.See Remarks | Received as pay | 133,333 | - |
| January 7, 2026 | Hoeiland JesperDirector | Received as pay | 25,000 | - |
Who owns ALLR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
5 insiders reported holding 1,223,378 shares in total, about $1.3M at the last price.
| Holder | Shares |
|---|---|
| Jensen ThomasCEO | 596,734 |
| Graff Jeremy R.See Remarks | 381,644 |
| Ervin Jeffrey SCFO | 150,000 |
| McLaughlin Gerald W.Director | 70,000 |
| Hoeiland JesperDirector | 25,000 |
Questions about ALLR
What does Allarity Therapeutics, Inc. do?
Allarity Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALLR.
Is Allarity Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $12.3M.
When did Allarity Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 16, 2026.
Similar companies
Compare ALLR with
Follow ALLR
Get an email when Allarity Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ALLR: get an email when it filesWhere the numbers come from
Financial figures are the values Allarity Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.